➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Mallinckrodt
Moodys
Baxter
Colorcon

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 8,580,253

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,580,253
Title:Immunomodulating compositions and methods of use
Abstract: This invention is directed to .beta.-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The .beta.-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.
Inventor(s): Rubin-Bejerano; Ifat (Belmont, MA), Fink; Gerald R. (Chestnut Hill, MA), Abeijon; Claudia (Worcester, MA), Kohane; Danial S. (Newton, MA), Fuller; Jason E. (Boston, MA), Langer; Robert S. (Newton, MA)
Assignee: Whitehead Institute (Cambridge, MA) Massachusetts Institute of Technology (Cambridge, MA) Trustees of Boston University (Boston, MA) The General Hospital Corporation (Boston, MA)
Application Number:12/513,830
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,580,253
Patent Claims:see list of patent claims

Details for Patent 8,580,253

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Whitehead Institute (Cambridge, MA) Massachusetts Institute of Technology (Cambridge, MA) Trustees of Boston University (Boston, MA) The General Hospital Corporation (Boston, MA) 2026-11-06 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Whitehead Institute (Cambridge, MA) Massachusetts Institute of Technology (Cambridge, MA) Trustees of Boston University (Boston, MA) The General Hospital Corporation (Boston, MA) 2026-11-06 RX search
Medimmune SYNAGIS palivizumab VIAL 103770 001 1998-06-19   Start Trial Whitehead Institute (Cambridge, MA) Massachusetts Institute of Technology (Cambridge, MA) Trustees of Boston University (Boston, MA) The General Hospital Corporation (Boston, MA) 2026-11-06 RX search
Medimmune SYNAGIS palivizumab VIAL 103770 002 1998-06-19   Start Trial Whitehead Institute (Cambridge, MA) Massachusetts Institute of Technology (Cambridge, MA) Trustees of Boston University (Boston, MA) The General Hospital Corporation (Boston, MA) 2026-11-06 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Whitehead Institute (Cambridge, MA) Massachusetts Institute of Technology (Cambridge, MA) Trustees of Boston University (Boston, MA) The General Hospital Corporation (Boston, MA) 2026-11-06 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Whitehead Institute (Cambridge, MA) Massachusetts Institute of Technology (Cambridge, MA) Trustees of Boston University (Boston, MA) The General Hospital Corporation (Boston, MA) 2026-11-06 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Johnson and Johnson
McKinsey
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.